Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity

Documenti analoghi

• Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes
  di: Zhimin Xu, et al.
  Pubblicazione: (2024)
• Impact of bariatric surgery on glycaemic and metabolic outcomes in people with obesity and type 2 diabetes mellitus: A meta‐analysis
  di: Xu Han, et al.
  Pubblicazione: (2025)
• Low‐Dose Glucagon After Fasted Morning Exercise in People With Type 1 Diabetes—A Randomised Crossover Comparison of Low and High Carbohydrate Diets
  di: Signe Schmidt, et al.
  Pubblicazione: (2026)
• Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism
  di: Nadan Gregorič, et al.
  Pubblicazione: (2024)
• Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes
  di: Michelle D. Lundholm, et al.
  Pubblicazione: (2024)